Shanghai Henlius Biotech, Inc. (2696.HK), a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co Ltd, announced on Thursday that the European Medicines Agency (EMA) has validated the application for the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab), in combination with chemotherapy (carboplatin and etoposide), intended for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
The European Commission (EC) has earlier granted Orphan Drug Designation (ODD) to the product for the treatment of small cell lung cancer (SCLC).
The company submitted the regulatory application based on data from ASTRUM-005, a randomised, double-blind, placebo-controlled international multi-centre phase three clinical study that assessed the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with ES-SCLC.
The study has set up 128 sites in various countries, including China, Poland, Turkey, and Georgia, and enrolled 585 subjects, among whom 31.5% were white. The results were presented orally at the 2022 ASCO annual meeting and were then published in the JAMA (impact factor of 157.3), demonstrating the high level of academic acclaim on a global scale.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial